Precigen to host a virtual r&d event on january 24th to share safety and efficacy data from the phase 1 dose escalation and expansion cohorts of prgn-2012 adenoverse™ immunotherapy in recurrent respiratory papillomatosis

Germantown, md. , jan. 4, 2023 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the company will host an investigator-led r&d event on january 24, 2023 at 4:30 pm et to showcase the latest clinical advancements for the company's investigational, first-in-class prgn-2012 off-the-shelf (ots) adenoverse™ immunotherapy in recurrent respiratory papillomatosis (rrp).
PGEN Ratings Summary
PGEN Quant Ranking